Log In
BCIQ
Print this Print this
 

Zalviso, sufentanil (ARX-01)

Also known as: Sublingual Sufentanil NanoTabs (formerly Sufentanil NanoTab PCA System)

  Manage Alerts
Collapse Summary General Information
Company AcelRx Pharmaceuticals Inc.
DescriptionPre-programmed, handheld device that delivers a sublingual formulation of sufentanil, a synthetic opioid analgesic
Molecular Target Opioid receptor (OPR)
Mechanism of ActionOpioid receptor agonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentMarketed
Standard IndicationPain
Indication DetailsManage postoperative pain in patients undergoing unilateral knee replacement surgery; Treat moderate to severe acute pain following knee replacement surgery; Treat moderate to severe acute pain in a hospital setting; Treat postoperative pain following major surgery; Treat postoperative pain following total unilateral knee or hip replacement surgery; Treat postoperative pain in patients undergoing major abdominal surgery
Regulatory Designation
PartnerGruenenthal Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$315.0M

$95.0M

$220.0M


 Deals Details
Get a free BioCentury trial today